CVTX - CV Therapeutics, Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (53)	11/12/2002 8:52:00 PM
From: mopgcw	Read Replies (2) of 411

SG conference summary: + Wed P2 data release for 3146, and early p3 next year. + NDA on renexa scheduled to be submitted this year, + CDT-510 P3 accepted as late-breaker for the conference, the psct sub-group met the endpoints, have proof of concept for P2 for atrial fibrillation, but doing more dosing work before p3 + 3 others in clinical + 3146 as stressing agent, dosing regimen is convenient compared to competition (bolus), collaboration w/ fujisawa who funds 75% of costs, cvtx does work so keeps it moving forward, and cvtx gets 20% royalties, plus a small royalty on another fujisawa product. + they are going to stay focused on cardiovascular + continue to "pay the freight" and capture the backend benefit, and pursuse specialized partner structures on a selected basis. corporate-ir.net

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next